Microwave ablation is as effective as radiofrequency ablation for very-early-stage hepatocellular carcinoma

Abstract

BackgroundPercutaneous radiofrequency ablation (RFA) is a first-line treatment for very-early-stage hepatocellular carcinoma (HCC), whereas the efficacy of percutaneous microwave ablation (MWA) for very-early-stage HCC remains unclear. The purpose of this study was to clarify this issue by comparing the safety and efficacy of percutaneous MWA with percutaneous RFA in treating very-early-stage HCC.MethodsClinical data of 460 patients who were diagnosed with very-early-stage HCC and treated with percutaneous MWA or RFA between January 2007 and July 2012 at the Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, in Shanghai, China were retrospectively analyzed. Of these 460 patients, 159 received RFA, 301 received MWA. Overall survival (OS), recurrence-free survival (RFS), local tumor progression (LTP), complete ablation, and complication occurrence rates were compared between the two groups, and the prognostic factors associated with survival were analyzed.ResultsNo significant differences were observed between the two groups in terms of the 1-, 3-, or 5-year OS rates (99.3%, 90.4%, and 78.3% for MWA vs. 98.7%, 86.8%, and 73.3% for RFA, respectively; P = 0.331). Furthermore, no significant differences were observed between the two groups in terms of the corresponding RFS rates (94.4%, 71.8%, and 46.9% for MWA vs. 89.9%, 67.3%, and 54.9% for RFA, respectively; P = 0.309), the LTP rates (9.6% vs. 10.1%, P = 0.883), the complete ablation rates (98.3% vs. 98.1%, P = 0.860), or the occurrence rates of major complications (0.7% vs. 0.6%, P = 0.691). By multivariate analysis, LTP, antiviral therapy, and treatment of recurrence were independent risk factors for OS (P < 0.001), and the alpha-fetoprotein level was an independent prognostic factor for RFS (P = 0.002).ConclusionsMWA is as safe and effective as RFA in treating very-early-stage HCC, supporting MWA as a first-line treatment option for this disease.

Comparison of microwave ablation and radiofrequency ablation for hepatocellular carcinoma: a systematic review and meta-analysis

“…For studies with duplicate data, reports with the lower number of patients and incomplete data were excluded. Finally, four RCTs [30][31][32][33] and 10 cohort studies [25,[34][35][36][37][38][39][40][41][42] with 1816 patients were included. All four RCTs focused on percutaneous ablation.…”

Latent Risk Intrahepatic Cholangiocarcinoma Susceptible to Adjuvant Treatment After Resection: A Clinical Deep Learning Approach

“…PRT was carried out using the same methodology as PAT. PRP was proceeded using an MTC-3 microwave generator (2,450 MHz, 1-100 W) at 80-100 W for 3-5 min automatically with a safety margin of 1 cm (20). Supportive information related to inclusion of patients for standardized performance of the procedures is described in the Supplementary Material.…”

Radyofrekansın kas iskelet sistemi hastalıklarında kullanımı

“…Pulse RFA'da elektrod ucunda yaklaşık 42°C'lere çıkan ısı depolanması gösterilmiş olmakla beraber, ağrıyı azaltıcı etkisi ve nöral dokuyu Vallerian dejenerasyonuna uğratma-dan kesme mekanizması tam olarak açık değildir. [6][7][8] Biz de, özellikle faset eklem blokajı işlemlerinde, servikal bölge için pulse RFA uygulamaktayız. Renal, karaciğer, akciğer tümörleri gibi birçok iç organ (visseral) tümörlerinde, genel durum bozukluğu olan hastalarda ağrı ve bazı semptomların geriletilmesinde ve ameliyat edilemeyen durumlarda dahi uygulama yeri mevcuttur.…”